TXMD News and Press, TherapeuticsMD Inc. From 03/11/22

Citing the ongoing supply issues affecting a key product, H.C. Wainwright has trimmed the price target of the women’s healthcare company, TherapeuticsMD (TXMD -3.1%) on Friday. After reporting worse-than-expected financials for Q4 2021, TherapeuticsMD (NASDAQ:TXMD) shares crashed ...

The following slide deck was published by TherapeuticsMD, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: TherapeuticsMD, Inc. 2021 Q4 - Results - Earnings Call Presentation

Image source: The Motley Fool. TherapeuticsMD, Inc. (NASDAQ: TXMD) Q4 2021 Earnings Call Mar 10, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: TherapeuticsMD, Inc. (TXMD) Q4 2021 Earnings Call Transcript

TherapeuticsMD, Inc. (TXMD) Q4 2021 Earnings Conference Call March 10, 2022, 08:30 AM ET Company Participants Lisa Wilson - Investor Relations Hugh O’Dowd - Chief Executive Officer James D’Arecca - Chief Financial Officer Mark Glickman - Chief Business Officer Conference Call Pa...

The shares of TherapeuticsMD (TXMD -20.2%) are trading sharply lower in morning hours after the women’s healthcare company reported lower than expected financials for Q4 2021. Revenue for the quarter at $18.7M missed average estimates of analysts by as much as $10.7M after a decli...

Therapeutics MD press release (NASDAQ:TXMD): Q4 GAAP EPS of -$0.10 misses by $0.02. Revenue of $18.67M (-17.4% Y/Y) misses by $10.72M. As of December 31, 2021, the Company’s cash on hand totaled $65.1 million, compared with $80.5 million as of December 31, 2020. Shares -2.88% PM. For...

- Reached definitive agreement to fully divest vitaCare business unit enabling greater focus on achieving leadership position in women’s healthcare - - Amended credit terms with Sixth Street in support of a new capitalization plan - - Conference call scheduled for 8:30 a.m. E...

Therapeutics MD (NASDAQ:TXMD) is scheduled to announce Q4 earnings results on Thursday, March 10th, before market open. The consensus EPS Estimate is -$0.08 and the consensus Revenue Estimate is $29.39M (+30.0% Y/Y). Over the last 1 year, TXMD has beaten EPS estimates 25% of the time and has ...

Buying Penny Stocks Today? Here’s What You Need to Know With another potentially volatile day of trading for penny stocks and blue chips, there is a lot for investors to consider. As we all know, the largest contributing factor to stock market movement right now is the war going ...

GoodRx has agreed to acquire vitaCare for $150 million in cash, with an additional $7 million consideration contingent upon vitaCare’s financial performance through 2023 TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an inno...